| Old Articles: <Older 5481-5490 Newer> |
|---|
 |
The Motley Fool
March 6, 2009
Brian Orelli |
Why the Buyback, Intuitive Surgical? Buybacks for high-growth companies like Intuitive Surgical aren't such a bad idea anymore.   |
The Motley Fool
March 5, 2009
Brian Orelli |
5 Stocks to Benefit From China's Health-Care Plan Same idea, different country. |
The Motley Fool
March 5, 2009
Brian Orelli |
The Dilemma for Drugmakers There's no safe place to hide. |
The Motley Fool
March 4, 2009
Brian Orelli |
Vertex Combines to Keep From Being Ground Up Vertex Pharmaceuticals announces that it is buying ViroChem Pharma, getting two early stage hepatitis C compounds in the deal. |
The Motley Fool
March 3, 2009
Robert Steyer |
Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company. |
The Motley Fool
March 3, 2009
Brian Orelli |
Pfizer Eyes Generic Growth Two partnerships in one day? Oh my! |
The Motley Fool
March 3, 2009
Brian Orelli |
Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think. |
The Motley Fool
March 3, 2009
Brian Orelli |
A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals. |
The Motley Fool
March 2, 2009
Brian Orelli |
Pharma's Public Relations Bonus: Executive Pay Bonuses? We don't need no stinkin' bonuses. |
Chemistry World
March 2009
Derek Lowe |
Column: In the pipeline The author worries that mergers are upsetting the balance of the pharmaceutical ecosystem |
| <Older 5481-5490 Newer> Return to current articles. |
